OncoMatch/Clinical Trials/NCT07686575
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
Is NCT07686575 recruiting? Yes, currently enrolling (Jul 2026). Studying Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） for hnscc.
Treatment: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） — To investigate the neoadjuvant chemoimmunotherapy regimen of Ivonescimab combined with chemotherapy (Paclitaxel plus Cisplatin/Carboplatin) for the treatment of locally advanced resectable oral squamous cell carcinoma and oropharyngeal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage STAGE III ORAL CANCER, STAGE IVA ORAL CANCER, HPV-NEGATIVE OROPHARYNGEAL CANCER, STAGE II HPV-POSITIVE OROPHARYNGEAL CANCER, STAGE III HPV-POSITIVE OROPHARYNGEAL CANCER (other)
Patients staged according to the AJCC criteria (8th edition) as locally advanced (Stage III/IVA oral cancer, HPV-negative oropharyngeal cancer, or Stage II/III HPV-positive oropharyngeal cancer) and assessed by the investigators as resectable.
Demographics
Lab requirements
Blood counts
WBC count ≥3×10⁹/L; Platelet count ≥75×10⁹/L; Hemoglobin concentration ≥80g/L
Kidney function
eGFR > 50 mL/min
Liver function
AST and ALT ≤2.5 times the upper limit of normal (ULN)
Cardiac function
adequate function of vital organs (including cardiac, pulmonary, thyroid, and other organs)
Complete blood count (CBC): WBC count ≥3×10⁹/L; Platelet count ≥75×10⁹/L; Hemoglobin concentration ≥80g/L; AST and ALT ≤2.5 times ULN; eGFR > 50 mL/min; adequate function of vital organs (including cardiac, pulmonary, thyroid, and other organs)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07686575 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage STAGE III ORAL CANCER or STAGE IVA ORAL CANCER or HPV-NEGATIVE OROPHARYNGEAL CANCER or STAGE II HPV-POSITIVE OROPHARYNGEAL CANCER or STAGE III HPV-POSITIVE OROPHARYNGEAL CANCER is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify